GLP-1 agonists – a class of medications such as Ozempic and Wegovy that can help manage Type 2 diabetes and obesity – have been making headlines for their effectiveness in weight loss. Keerthana Kesavarapu and Kunal Shah, two professors from the Rutgers Robert Wood Johnson Medical School who lead the Rutgers Center of Metabolic Health and Weight Management, discuss the implications for obesity treatment – and how to maximize the impact. To read the full interview.